NervGen Starts Phase 3 Spinal Cord Injury Trial

The trial tests a regenerative peptide, as a family-founded group works to speed FDA approval of spinal cord injury treatments.

Updated on Nov. 17, 2026 in Stroke

Bold vector editorial illustration of an ivory vertebral column with a small sealed amber vial at its base on a slate surface.
NervGen has started a Phase 3 clinical trial of its regenerative peptide for spinal cord injury, as the Scherb family founded BreakThru SCI to speed FDA approval of treatments. AI Illustration. Upload story photo >

NervGen has started a Phase 3 clinical trial of its regenerative peptide for spinal cord injury. The effort comes as the Scherb family founded BreakThru SCI to accelerate FDA approval of treatments for the condition.

Why it matters

Spinal cord injuries currently have no approved therapies that restore function, so progress through late-stage trials could change treatment options for patients. If a first drug is approved, the field may attract more development and investment from large biotech companies.

Animal studies reported that paralyzed mice or rats could walk within four weeks after one injection of Dancing Molecules, while patients may wait five to seven years for access. Whether these results will hold in human trials remains unknown.

The players

NervGen

NervGen is a biotechnology company developing regenerative therapies for spinal cord injury.

BreakThru SCI

BreakThru SCI is a group founded by the Scherb family to advance FDA approval of spinal cord injury drugs.

Northwestern University

Northwestern University is a private research university in Evanston, Illinois, where Dancing Molecules is being developed.

The details

Clay Scherb was injured in a shallow-water diving accident in August 2022 and later qualified for NervGen's Phase 2 trial at Shirley Ryan AbilityLab in Chicago. Dancing Molecules is being developed at Northwestern University, with Amphix Bio involved in moving it toward human trials.

Timeline

  1. August 2022: Clay Scherb suffers a cervical spinal cord injury in a diving accident.

  2. More than a year after the accident: Scherb qualifies for the NervGen Phase 2 trial.

  3. Summer 2025: The Scherb family founds BreakThru SCI.

Health Landscape

Spinal cord injuries have lacked an FDA-approved restorative therapy, and this Phase 3 trial represents one of the advanced steps toward changing that. BreakThru SCI's focus on FDA approval reflects the broader effort to move regenerative candidates through the agency's review process.

For people living with spinal cord injuries, these trials represent a possible future path to restored function rather than management alone. Access to experimental treatments may depend on trial enrollment, so patients interested in participation should consult their care teams.

The takeaway

Progress in spinal cord injury research depends on advancing promising candidates through rigorous late-stage trials. Patients and families should track trial developments through reputable medical sources as results emerge.

Further reading

Explore more on Stroke and related neurological recovery research.

Source note: This article includes information reported by NBC Chicago.